Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 101–200 of 1,000
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
“EZH2 and DNMT1 inhibitors increased Th1-type chemokines and T-cell infiltration, and augmented the efficacy of PD-L1 blockade therapy in vivo (332).”
BackgroundThe Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
“Moreover, the migration of CD8+ T cells into the tumor environment is diminished due to impaired expression of the T helper 1-associated chemokines CXCL9 and CXCL10.”
BackgroundInfluentialPetty, A. J., Li, A., Wang, X., Dai, R., Heyman, B., Hsu, D., Huang, X., & Yang, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128644 · Cited by 287
“However, we cannot exclude the possibility that tumor-derived CXCL9 and CXCL10 may also play a role in regulating CD8+ T cell infiltration, as a previous report has demonstrated that epigenetic silencing of CXCL9 and CXCL10 production from tumor cells significantly reduces CD8+ T cell infiltration into the tumor strom…”
BackgroundSugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 289
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
“One preclinical study of ovarian cancer showed that agents used to reprogram epigenetic pathways such as DZNep (an EZH2 inhibitor) and DNMT inhibitors alters the tumormicroenvironment so that T cell infiltration is increased [57].”
BackgroundMetabolism shapes the tumor microenvironment
Reina-Campos, M., Moscat, J., & Diaz-Meco, M. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.05.006 · Cited by 293
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 280
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond
Karin, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00976 · Cited by 278
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
“Other work has demonstrated that molecules involved in epigenetic modifications can modulate tumor antigen expression [110] or suppress T cell infiltration in tumors [111,112] and, therefore, comprise additional candidates for combinations with checkpoint inhibitors.”
BackgroundAsrir, A., Tardiveau, C., Coudert, J., Laffont, R., Blanchard, L., Bellard, E., Veerman, K., Bettini, S., Lafouresse, F., Vina, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.002 · Cited by 257
Lung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 283
How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Yu, J., Song, Y., & Tian, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00876-4 · Cited by 269
“lencing genes such as enhancer of zeste homolog 2 (EZH2) [58], and/or secrete a large amount of soluble immune suppressive factors such as TGF-β and VEGF [59, 60].”
BackgroundStrength Model of Self-Regulation as Limited Resource
Baumeister, R. F., & Vohs, K. D. (2016) · Advances in Experimental Social Psychology · doi:10.1016/bs.aesp.2016.04.001 · Cited by 237
“Moreover, recent evidence suggests that an excess of blood glucose can serve as inviting fuel for pathogens, from bacterial infections to cancer (Peng et al., 2015; Rayfield et al., 1982).”
BackgroundSchulz, D., Zanotelli, V. R. T., Fischer, J. R., Schapiro, D., Engler, S., Lun, X.-K., Jackson, H. W., & Bodenmiller, B. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.001 · Cited by 280
“We observed most of the mRNA expression in stromal cells, in contrast to previous studies in which CXCL10 protein staining was often observed in the epithelial compartment (Bai et al., 2016; Duruisseaux et al., 2017; Mulligan et al., 2013; Peng et al., 2015).”
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
Promises and challenges of adoptive T-cell therapies for solid tumours
Morotti, M., Albukhari, A., Alsaadi, A., Artibani, M., Brenton, J. D., Curbishley, S. M., Dong, T., Dustin, M. L., Hu, Z., McGranahan, N., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01353-6 · Cited by 269
Zhou, L., Mudianto, T., Ma, X., Riley, R., & Uppaluri, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1351 · Cited by 269
“Consistent with findings in ovarian cancer (20), we also observed a significant induction of CXCL10 expression in EZH2 inhibitor–treated cells compared with DMSO control that was dramatically enhanced in combination with IFNg (Fig.”
BackgroundPang, K., Shi, Z.-D., Wei, L.-Y., Dong, Y., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J.-J., Chen, Y.-A., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 260
Self-citationPascual-García, M., Bonfill-Teixidor, E., Planas-Rigol, E., Rubio-Perez, C., Iurlaro, R., Arias, A., Cuartas, I., Sala-Hojman, A., Escudero, L., Martínez-Ricarte, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10369-9 · Cited by 262
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Vredevoogd, D. W., Kuilman, T., Ligtenberg, M. A., Boshuizen, J., Stecker, K. E., de Bruijn, B., Krijgsman, O., Huang, X., Kenski, J. C. N., Lacroix, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.014 · Cited by 259
Morel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00185-w · Cited by 250
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Eich, M.-L., Athar, M., Ferguson, J. E., & Varambally, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2147 · Cited by 242
“Peng and colleagues determined that EZH2-mediated transcriptional silencing of the cytokines CXCL9 and CXCL10 prevents efficient T-cell trafficking in ovarian cancer cell xenograft models, and can be reversed by EZH2 inhibition in combination with anti–PD-L1 checkpoint blockade (99).”
BackgroundPRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Kim, H., Kim, H., Feng, Y., Li, Y., Tamiya, H., Tocci, S., & Ronai, Z. A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5683 · Cited by 232
“Impaired recruitment of CD8 T cells to tumors can also be mediated by epigenetic factors, namely, EZH2 (histone-lysine N-methyltransferase)–mediated repression of chemokines (CXCL9 and CXCL10) or LSD1 (lysine-specific histone demethylase)–mediated repression of type I interferon (IFN) response (7, 8).”
BackgroundModulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99760 · Cited by 244
“As EZH2 regulates expression of Th-1 chemokines such as CXCL9 and CXCL10 in the tumor cells (14), we performed in vitro (cell line) and in vivo (murine tumor model) experiments to assess the contribution of CXCL9 and CXCL10 in our system.”
MethodCancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M., & de Miranda, N. F. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 240
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 237
Ye, S., Zhang, H., Cai, T., Liu, Y., Ni, J., He, J., Peng, J., Chen, Q., Mo, H., Jun‐Cui, et al. (2016) · The Journal of Pathology · doi:10.1002/path.4781 · Cited by 238
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown, J. S., Sundar, R., & Lopez, J. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.376 · Cited by 231
Moreno Ayala, M. A., Campbell, T. F., Zhang, C., Dahan, N., Bockman, A., Prakash, V., Feng, L., Sher, T., & DuPage, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.003 · Cited by 241
Do, H. T. T., Lee, C. H., & Cho, J. (2020) · Cancers · doi:10.3390/cancers12020287 · Cited by 234
The Contribution of Epigenetics to Cancer Immunotherapy
Villanueva, L., Álvarez-Errico, D., & Esteller, M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.002 · Cited by 235
Targeting EZH2 in cancer therapy
Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 225
Duruisseaux, M., Martínez-Cardús, A., Calleja-Cervantes, M. E., Moran, S., Castro de Moura, M., Davalos, V., Piñeyro, D., Sanchez-Cespedes, M., Girard, N., Brevet, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30284-4 · Cited by 224
“36,37 Most importantly, DNA demethylating agents and other epigenetic drugs, such as histone deacetylase inhibitors, have been clinically approved for use in the treatment of some subtypes of leukemias and lymphomas.”
Zhang, Q., Green, M. D., Lang, X., Lazarus, J., Parsels, J. D., Wei, S., Parsels, L. A., Shi, J., Ramnath, N., Wahl, D. R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0761 · Cited by 226
“Loss of interferon signaling compromises anti-tumoral immunity, and patients with an interferon signature are more likely to clinically benefit from immune checkpoint (47).”
BackgroundSelf-citationQin, Y., Vasilatos, S. N., Chen, L., Wu, H., Cao, Z., Fu, Y., Huang, M., Vlad, A. M., Lu, B., Oesterreich, S., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0451-5 · Cited by 215
Cellular architecture of human brain metastases
Gonzalez, H., Mei, W., Robles, I., Hagerling, C., Allen, B. M., Hauge Okholm, T. L., Nanjaraj, A., Verbeek, T., Kalavacherla, S., van Gogh, M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.043 · Cited by 219
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M., Sun, H., Morton, G., Madzo, J., Chung, W., Khowsathit, J., Perez-Leal, O., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 222
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 205
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
“In support of these findings, combining epigenetic modulators including DNA methyltransferase inhibitors and histone deacetylase inhibitors has been shown to improve the therapeutic potential of ICIs [125, 134].”
Gao, Y., Yang, J., Cai, Y., Fu, S., Zhang, N., Fu, X., & Li, L. (2018) · International Journal of Cancer · doi:10.1002/ijc.31357 · Cited by 217
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
Shen, D.-D., Pang, J.-R., Bi, Y.-P., Zhao, L.-F., Li, Y.-R., Zhao, L.-J., Gao, Y., Wang, B., Wang, N., Wei, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01557-1 · Cited by 200
“The number of cells vary by activation and proliferation or exhaustion and apoptosis of CD8+ T cells, which can be induced by other cells or factors in the tumor microenvironment [37, 38].”
BackgroundSelf-citationExosomes as Reconfigurable Therapeutic Systems
Conlan, R. S., Pisano, S., Oliveira, M. I., Ferrari, M., & Mendes Pinto, I. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.05.003 · Cited by 209
“In addition, recent research has demonstrated that treatment of human ovarian cancer with sub-cytotoxic levels of decitabine -- a DNA methyltransferase (DNMT) epigenetic inhibitor (used to treat myelodysplastic syndromes and acute myeloid leukemia), --triggered cytokine release from tumor cells; this resulted in cytot…”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Current Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Self-citationCancer immunotherapy: Challenges and limitations
Taefehshokr, S., Parhizkar, A., Hayati, S., Mousapour, M., Mahmoudpour, A., Eleid, L., Rahmanpour, D., Fattahi, S., Shabani, H., & Taefehshokr, N. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153723 · Cited by 195
Li, F., Huang, Q., Luster, T. A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0780 · Cited by 203
Self-citationPérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
“Interestingly, EZH2 is also key in this process, since it determines the binding of FOXP3 (Forkhead Box P3) in activated Treg, and the consequent FOXP3-driven gene expression program that produces immune tolerance (Peng et al., 2015).”
BackgroundStudy and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 195
Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R., Jinushi, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.017 · Cited by 198
Chen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 197
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Liu, Z., Zhou, Z., Dang, Q., Xu, H., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 189
Hou, J., Zhang, H., Sun, B., & Karin, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.014 · Cited by 193
Argyle, D., & Kitamura, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02629 · Cited by 190
“A recent study using mouse models of ovarian cancer has shown that the reduced production of CXCL9 and CXCL10 from cancer cells is caused by enhancer of zeste homolog 2 (EZH2) mediated histone modification and DNA methyltransferase 1 (DNMT1) mediated DNA methylation of the chemokine genes (129).”
BackgroundZhong, W., Myers, J. S., Wang, F., Wang, K., Lucas, J., Rosfjord, E., Lucas, J., Hooper, A. T., Yang, S., Lemon, L. A., et al. (2020) · BMC Genomics · doi:10.1186/s12864-019-6344-3 · Cited by 184
LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
Li, G., Kryczek, I., Nam, J., Li, X., Li, S., Li, J., Wei, S., Grove, S., Vatan, L., Zhou, J., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00672-3 · Cited by 197
“IFN γ signaling pathway plays a key role in determining therapeutic response to cancer immunotherapy 40 via multiple mechanisms 19,20,41,42 .”
Self-citationEpigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191
“EZH2 mediates CXCL9 and CXCL10 repression in tumor cells through H3K27me3 (28).”
BackgroundInfluentialSelf-citationEpigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 189
Yamagishi, M., Hori, M., Fujikawa, D., Ohsugi, T., Honma, D., Adachi, N., Katano, H., Hishima, T., Kobayashi, S., Nakano, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.083 · Cited by 188
Falahat, R., Berglund, A., Putney, R. M., Perez-Villarroel, P., Aoyama, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013598118 · Cited by 190
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 192
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Dangaj Laniti, D., & Coukos, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00503-z · Cited by 180
IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment
Fang, M., Li, Y., Huang, K., Qi, S., Zhang, J., Zgodzinski, W., Majewski, M., Wallner, G., Gozdz, S., Macek, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1602 · Cited by 187
“IL-33 expression levels were assessed using H-score as we previously described (22,23,25).”
Self-citationGordon-Alonso, M., Hirsch, T., Wildmann, C., & van der Bruggen, P. (2017) · Nature Communications · doi:10.1038/s41467-017-00925-6 · Cited by 186
Huang, S., Wang, Z., Zhou, J., Huang, J., Zhou, L., Luo, J., Wan, Y. Y., Long, H., & Zhu, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2395 · Cited by 185
“2 mg/kg) resulted in TME reprograming, the production of Th 1–type chemokines CXCL9 and CXCL10 in the tumor, and increased tumor infiltration of CD8þ T cells (34, 35).”
BackgroundEZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Xiao, G., Jin, L.-L., Liu, C.-Q., Wang, Y.-C., Meng, Y.-M., Zhou, Z.-G., Chen, J., Yu, X.-J., Zhang, Y.-J., Xu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0784-9 · Cited by 179
Liu, X.-D., Kong, W., Peterson, C. B., McGrail, D. J., Hoang, A., Zhang, X., Lam, T., Pilie, P. G., Zhu, H., Beckermann, K. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15959-6 · Cited by 177
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
“Previous studies have found that EZH2 can repress the expression and subsequent production of Th1-type chemokines CXCL9 and CXCL10, thus preventing efficient T-cell trafficking to tumors, a process that can be reversed by EZH2 inhibition in combination with anti-PD-L1 checkpoint blockade.(513,515) Through its epigenet…”
BackgroundZhang, Q.-F., Li, J., Jiang, K., Wang, R., Ge, J.-L., Yang, H., Liu, S.-J., Jia, L.-T., Wang, L., & Chen, B.-L. (2020) · Theranostics · doi:10.7150/thno.44871 · Cited by 177
“To evaluate the potential and possible mechanism of a CDK4/6i and checkpoint blockade combination for ovarian cancer treatment, a widely used ID8 tumor-bearing mouse model [26,27] was used in our research.”
MethodLo, C. S., Sanii, S., Kroeger, D. R., Milne, K., Talhouk, A., Chiu, D. S., Rahimi, K., Shaw, P. A., Clarke, B. A., & Nelson, B. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1433 · Cited by 172
“The mechanistic basis for this immunologically inert phenotype is unknown but could reflect lymphocyte infiltration barriers, hostile vasculature, immunosuppressive signaling pathways, unfavorable epigenetic patterns, or other factors that, with better understanding, could potentially be reversed (2, 8, 44, 45).”
BackgroundKDM5 histone demethylases repress immune response via suppression of STING
Wu, L., Cao, J., Cai, W. L., Lang, S. M., Horton, J. R., Jansen, D. J., Liu, Z. Z., Chen, J. F., Zhang, M., Mott, B. T., et al. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2006134 · Cited by 172
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 173
“Indeed, increased levels of chemokine receptors on T cells were shown to increase anti-tumor response to PD-1 therapy [51] whereas reduced chemokine expression by tumor cells increase resistance [27].”
BackgroundQu, K., Zaba, L. C., Satpathy, A. T., Giresi, P. G., Li, R., Jin, Y., Armstrong, R., Jin, C., Schmitt, N., Rahbar, Z., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.008 · Cited by 175
“Recent studies of EZH2 and DNA methyltransferase inhibitors have shown an important role in de-repressing host immunity against cancer in preclinicalmodels (Chiappinelli et al., 2015; Peng et al., 2015).”
Tumor-induced generation of splenic erythroblast-like Ter-cells promotes tumor progression.
Han, Y., Liu, Q., Hou, J., Gu, Y., Zhang, Y., Chen, Z., Fan, J., Zhou, W., Qiu, S., Zhang, Y., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.061 · Cited by 150
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Combining epigenetic and immune therapy to overcome cancer resistance
Gomez, S., Tabernacki, T., Kobyra, J., Roberts, P., & Chiappinelli, K. B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.019 · Cited by 160
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Kline, J., Godfrey, J., & Ansell, S. M. (2020) · Blood · doi:10.1182/blood.2019000847 · Cited by 167
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
“Recent studies demonstrate that tumor genetic and epigenetic mutations (Li et al., 2020; Mandal et al., 2019; Peng et al., 2015), mutations in interferon (IFN)γ and MHC signaling pathway (Gao et al.”
BackgroundSelf-citationMalignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover
Krejsgaard, T., Lindahl, L. M., Mongan, N. P., Wasik, M. A., Litvinov, I. V., Iversen, L., Langhoff, E., Woetmann, A., & Odum, N. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0594-9 · Cited by 159
“CXCL10, in ovarian and colorectal cancers, thereby reducing recruitment of CD8 T cells [162, 165].”
BackgroundJia, L., Zhang, W., & Wang, C. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.06.022 · Cited by 167
“The inhibition of PRC2-mediated histone H3 lysine 27 trimethylation, leads to increased responses to cancer immunotherapy (Nagarsheth et al., 2016; Peng et al., 2015).”
Enhancing Tumor T Cell Infiltration to Enable Cancer Immunotherapy
Zhang, J., Endres, S., & Kobold, S. (2019) · Immunotherapy · doi:10.2217/imt-2018-0111 · Cited by 158
Xia, H., Wang, W., Crespo, J., Kryczek, I., Li, W., Wei, S., Bian, Z., Maj, T., He, M., Liu, R. J., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan4631 · Cited by 150
“RNA extraction, reverse transcription, and real-time polymerase chain reaction RNA extraction, reverse-transcription, and real-time polymerase chain reaction (PCR) were described previously (52).”
MethodSelf-citationTan, Y. S., Sansanaphongpricha, K., Xie, Y., Donnelly, C. R., Luo, X., Heath, B. R., Zhao, X., Bellile, E., Hu, H., Chen, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2807 · Cited by 150
“ISGs include Th1 chemokines, such as CXCL10, which recruit APC and effectors to the tumor bed (7, 12).”
BackgroundThe spatio-temporal control of effector T cell migration
Fowell, D. J., & Kim, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00507-0 · Cited by 167
Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
Havasi, A. D., Cainap, S. S., Havasi, A. T., & Cainap, C. I. (2023) · Medicina · doi:10.3390/medicina59030544 · Cited by 177
“Combined EZH2 and DNMT1 inhibition increased effector T-cell tumor infiltration, inhibited tumor progression, and improved the therapeutic efficacy of PDL-1 blockade [147].”
BackgroundEpi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Mazzone, R., Zwergel, C., Mai, A., & Valente, S. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0358-y · Cited by 149
“For instance, combination of EZH2 inhibitors such as deazaneplanocin A (DZNep) or tazemetostat (EPZ6438) with 5-AZA displayed improved therapeutic efficacy of anti-PD-L1 treatment by increasing Teff tumour infiltration and decreasing tumour progression [102].”
BackgroundVey, N., Karlin, L., Sadot-Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24832 · Cited by 142
“In addition, hypomethylating drugs (5-azacytidine or decitabine) that are currently approved as treatments for AML and MDS have shown immunomodulatory effects, including enhanced production of Th1-type chemokines [26] and up-regulation of NKG2D ligand (MICA/B, ULBP) expression [27, 28].”
BackgroundOff-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
Sætersmoen, M., Hammer, Q., Valamehr, B. B., Kaufman, D. S., & Malmberg, K. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0721-x · Cited by 157
Reactive oxygen species-powered cancer immunotherapy: Current status and challenges
He, M., Wang, M., Xu, T., Zhang, M., Dai, H., Wang, C., Ding, D., & Zhong, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.040 · Cited by 150
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Han, J., Wu, M., & Liu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190333 · Cited by 169
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Wang, Q., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.015 · Cited by 154
Chemokines and cancer: new immune checkpoints for cancer therapy
Karin, N. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.004 · Cited by 158
IFNγ signaling integrity in colorectal cancer immunity and immunotherapy
Du, W., Frankel, T. L., Green, M., & Zou, W. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00735-3 · Cited by 143
Self-citationcircFAT1 Promotes Cancer Stemness and Immune Evasion by Promoting STAT3 Activation
Jia, L., Wang, Y., & Wang, C. (2021) · Advanced Science · doi:10.1002/advs.202003376 · Cited by 159
Prospects for combining immune checkpoint blockade with PARP inhibition
Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0784-8 · Cited by 143
“Secondly, type I IFN stimulates the secretion of Th1 chemokines such as C-X-C motif chemokine ligand 9 (CXCL9) and C-X-C motif chemokine ligand 10 (CXCL10) which further promote the trafficking of T cells [105].”
Background
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.